Filing Details
- Accession Number:
- 0000939767-17-000073
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-03 20:02:16
- Reporting Period:
- 2017-05-01
- Filing Date:
- 2017-05-03
- Accepted Time:
- 2017-05-03 20:02:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 939767 | Exelixis Inc. | EXEL | Services-Commercial Physical & Biological Research (8731) | 043257395 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1213140 | Gisela Schwab | C/O Exelixis, Inc. 210 E. Grand Ave. South San Francisco CA 94080 | Pres Prod Dev & Med Aff & Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-05-01 | 89,910 | $9.91 | 260,414 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-05-01 | 88,010 | $23.00 | 172,404 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-05-01 | 1,900 | $23.31 | 170,504 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option (right to buy) | Disposition | 2017-05-01 | 89,910 | $0.00 | 89,910 | $9.91 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 100,000 | 2008-12-06 | 2017-12-05 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 14,186 | Indirect | By 401(k) |
Footnotes
- Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 2,361 shares of common stock acquired on April 28, 2017, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2017.
- Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.23 to $23.21. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.24 to $23.37. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
- Represents 14,186 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 1, 2017.
- The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011.
Billionaire Hedge Funds
